TECHNOLOGY FOR SOCIAL IMPACT

We share a mission

Improve the quality of life of the people

We are an interdisciplinary group that works to make technologies that provide a better quality of life to the people. Our motivation is people, so we work hard to improve day by day with you. Get to know us.

David Blánquez

CEO

Salva Gutiérrez 

CFO

Xavier Raurich 

COO

Ernest Montañà 

Chief Technology Officer

Jordina Arcal

Chief Strategy Officer

Dra. Gloria Durán

Chief Medical Officer

Jesús Valls

AI Engineer

Lluís Munsó

AI Engineer

Clara Gelabert

Accounting & Administrative

Fernando Atienza 

Quality Manager

Anna Rodríguez

Sales & Marketing

Marina Blánquez

Marketing Assistant

Fran Arzu

Web Developer

Juan Balsa

AI Engineer

PhD Beatriz López

PhD Artificial Intelligence

Luismi Aras

Dr. Medicina, CEO Apoyo Dravet

Adrián Trejo

Director Neurociencias Corachan

Slide Xavier Raurich COO
Slide David Blánquez CEO Slide Salva Gutiérrez CFO
Founders

Slide Ernest Montañà Chief Technology Officer Slide Jordina Arcal Chief Strategy Officer Slide Dra. Gloria Durán Chief Medical Officer Slide Jesús Valls AI Engineer Slide Lluís Munsó AI Engineer Slide Clara Gelabert Accounting & Administrative Slide Fernando Atienza Quality Manager Slide Anna Rodríguez Sales & Marketing Slide Marina Blánquez
Marketing Assistant
Slide Fran Arzu
Web Developer
Slide Juan Balsa AI Engineer
Team

Slide PhD Beatriz López PhD Artificial Intelligence Slide Luismi Aras Dr. Medicina, CEO Apoyo Dravet Slide Adrián Trejo Director Neurociencias Corachan Advisory Board
An unquestionable objective

We have very clear objectives.

We only understand technological development if it has a social impact, which is why we spend part of our income to R+D projects and part of our profits to social action.

mjn-neuro has a positive impact on our society, as we explain in our Theory of Social Change. Also, we will periodically measure our impact and publish the results obtained. Discover the importance of social change in MJN.

5

of our profit will be dedicated to promote social projects

10

of our sales will go to research and innovation

Awards and recognitions

This international certificate recognizes that mjn-neuro is compliant with all requirements specified to sell and provide medical products and services.

This certificate indicates that the solution developed by mjn-neuro to evaluate the risk of epilepsy seizures is a medical device that complies with directive 93/42/EEC.

Our commitment to excellence

Everything we do in mjn-neuro is compliant with the highest quality standards.

mjn-neuro has the ISO 13485:2016 quality certificate, the Manufacturer’s License from the Spanish Agency of Medicines and Health Products and the CE certificate as a class IIa medical device. You can also read our quality policy here.

Our team

Get to know the mjn-neuro team

Corporation

Milestones 2020

We are coming to the end of 2020, we would like to congratulate everyone who has helps us in our…
Corporation

Interview with David Blánquez, CEO at mjn-neuro

Yes! We did it! We have been able to “steal” few minutes from our CEO, David Blánquez. You started as…
Corporation

Interview with Xavier Raurich, COO at MJN

We introduce you to Xavier, the COO (Chief Operating Officer) of MJN. Xavier has been one of the founders of…
See all the interviews

Do you imagine being able to know at any time the risk of suffering a seizure?

Our collaborators

We are not alone helping people with epilepsy

Grant programs

Horizon 2020, SME Instruments 2018-2020. Grant 849781

Project: Seizure Risk Assessment for epilepsy
See more

Retos Colaboración MJN-eXiT (Universitat de Girona)

Project: mjn-SERAS, Device for the evaluation of the risk of epileptic seizures

The main objective of the project is to improve the quality of life of patients with epilepsy through the development of a solution that will be capable of detecting and alerting epilepsy seizures suffered by this type of patient and thereby avoiding accidents resulting from these situations.

To achieve this objective, the project collaborates with the company mjn-neuro, which will take the lead into this initiative. The project will also count on the UDG eXiT Research Group who has a long experience in creating predictive methods from biomedical data.

Project funded by FEDER / Ministry of Science, Innovation, and Universities – State Research Agency / Project (RTC-2017-6701-1).

The main objective of this call is to promote technological development, innovation and quality research.

See more

"Misiones CDTI" program

Project: Dreamer: EARLY DETECTION OF ALZHEIMER'S

Project for the early detection of signs that allow the diagnosis of Alzheimer’s disease in the preclinical phase, through cognitive markers and electroencephalographic records, with the development of a portable and
non-invasive device and the use of artificial intelligence.

The project has a duration of three years (01/10/2020 – 31/12/2022) and is carried out entirely in Catalonia by the participants ELAUSA ELECTRONICA I AUTOMATISMES S.L., INSTITUTO MEDICO PRIVADO, S.L.P., MJN NEUROSERVEIS S.L. y WEIRD KIN S.L.
It has a budget of €2,095,799 and a grant of €1,444,491.15.
Document: EXP 00135659 / MIP_20201050
DREAMER is a project subsidised by the CDTI with the support of the Ministry of Science and Innovation.

Subsidised by CDTI

Stories

From the people who best know about epilepsy

A world of inspiration
Blog

At mjn-neuro talk about epilepsy in all forums and all languages

Go to blog